GAMMA Investing LLC Has $6.49 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

GAMMA Investing LLC lifted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 1,746.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 65,514 shares of the company’s stock after purchasing an additional 61,966 shares during the period. GAMMA Investing LLC’s holdings in Roivant Sciences were worth $6,493,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. FMR LLC grew its holdings in Roivant Sciences by 0.3% in the 4th quarter. FMR LLC now owns 49,301,583 shares of the company’s stock valued at $583,238,000 after buying an additional 156,527 shares in the last quarter. Vanguard Group Inc. raised its position in Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after purchasing an additional 2,404,232 shares during the last quarter. Patient Square Capital LP raised its position in Roivant Sciences by 2.1% in the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company’s stock valued at $147,638,000 after purchasing an additional 251,535 shares during the last quarter. Two Seas Capital LP raised its position in shares of Roivant Sciences by 4.6% during the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company’s stock worth $120,285,000 after acquiring an additional 442,914 shares during the last quarter. Finally, Invesco Ltd. raised its position in shares of Roivant Sciences by 49.7% during the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company’s stock worth $112,563,000 after acquiring an additional 3,159,603 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In other news, COO Eric Venker sold 434,478 shares of the business’s stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the transaction, the chief operating officer now directly owns 1,127,290 shares of the company’s stock, valued at approximately $12,197,277.80. The trade was a 27.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of the firm’s stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total value of $3,142,309.73. Following the completion of the transaction, the insider now owns 39,799,611 shares of the company’s stock, valued at approximately $456,501,538.17. The trade was a 0.68% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 2,972,189 shares of company stock worth $33,059,785. 7.90% of the stock is currently owned by corporate insiders.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $11.08 on Tuesday. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06. The stock has a market capitalization of $7.91 billion, a PE ratio of -73.86 and a beta of 1.16. The business’s fifty day moving average price is $10.66 and its 200-day moving average price is $11.00.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.15). The company had revenue of $7.57 million for the quarter, compared to the consensus estimate of $62.17 million. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. As a group, equities analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

ROIV has been the subject of a number of research analyst reports. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, May 28th.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.